Modulating Post-Stroke Inflammation with FDA-Approved Immunotherapies: A Literature Review
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27041700 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Eduardo Álvarez-Rivera und 18 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology and Immunology Department, Universidad Central del Caribe, Bayamón, PR 00960-6032, USA. Hauptthemen laut MEDLINE: Stroke, Immunotherapy, Inflammation, Neuroinflammatory Diseases. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Stroke has been a topic of extensive research due to its debilitating consequences and high mortality. New findings offer a deeper understanding of specific factors that affect post-stroke recovery and identify therapies that may facilitate this process. One such factor is post-stroke neuroinflammation, a complex and time-dependent process in which acute immune responses can cause significant secondary inflammatory damage if the process is prolonged. Microglia are neuronal immune cells that are highly reactive to cytokines in the neuroenvironment and can, in turn, affect the inflammatory cascades that originate after stroke, making them ideal candidates for immunomodulation in the brain. Many FDA-approved immunotherapies have been found to target distinct inflammatory signaling molecules and responders, including IL-6 inhibitors, IL-13 inhibitors, IL-12/IL-23 inhibitors, B-cell modulators, type I interferon inhibitors, CAR T-cell therapy, calcineurin inhibitors, complement inhibitors, and JAK-STAT pathway inhibitors. The FDA-approved immunotherapies discussed in this review demonstrate potential in modulating the immune response after stroke by targeting key inflammatory pathways involved in secondary brain injury. Future research should focus on defining optimal therapeutic windows, identifying suitable patient populations, determining the most appropriate timing of therapy, and targeting specific immune mechanisms to balance the attenuation of harmful inflammation with the preservation of reparative processes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Microbiology and Immunology Department, Universidad Central del Caribe, Bayamón, PR 00960-6032, USA.
- School of Medicine, Universidad Central del Caribe, Bayamón, PR 00960-6032, USA.
- Department of Science and Technology, Interamerican University, San Juan, PR 00919-1293, USA.
- Department of Biology, University of Puerto Rico, San Juan, PR 00925-253, USA.
- Neuroscience Department, Universidad Central del Caribe, Bayamón, PR 00960-6032, USA.
ORCID-Profile: Eduardo Álvarez-Rivera, Solianne Martínez-Jiménez
Zitieren
APA
Álvarez-Rivera, E., Rodríguez-Vega, P., Colón-Santiago, F., Romero-Ponce, A., Umpierre-Lebrón, F., Roig-Opio, P., González-Fernández, A., Rosa-Arocho, T., Santiago-Rodríguez, L., Martínez-Torres, A., Santiago-González, G. G., Llorens-Mercado, J., Acevedo-Rico, J., Bermúdez-Fosse, V., Hernández-Santisteban, N., Rodríguez-Castellanos, C., García-Calderín, C., Gómez-Irrizary, F., & Martínez-Jiménez, S. (2026). Modulating Post-Stroke Inflammation with FDA-Approved Immunotherapies: A Literature Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041700
Vancouver
Álvarez-Rivera E, Rodríguez-Vega P, Colón-Santiago F, Romero-Ponce A, Umpierre-Lebrón F, Roig-Opio P, et al. Modulating Post-Stroke Inflammation with FDA-Approved Immunotherapies: A Literature Review. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041700
BibTeX
@article{lvarezRivera2026,
author = {Álvarez-Rivera, Eduardo and Rodríguez-Vega, Pamela and Colón-Santiago, Fabiola and Romero-Ponce, Armeliz and Umpierre-Lebrón, Fabiola and Roig-Opio, Paola and González-Fernández, Aitor and Rosa-Arocho, Tiffany and Santiago-Rodríguez, Laura and Martínez-Torres, Ana and Santiago-González, Gerson G and Llorens-Mercado, James and Acevedo-Rico, Jordan and Bermúdez-Fosse, Victoria and Hernández-Santisteban, Naiara and Rodríguez-Castellanos, Claudia and García-Calderín, Carola and Gómez-Irrizary, Fabyana and Martínez-Jiménez, Solianne},
title = {Modulating Post-Stroke Inflammation with FDA-Approved Immunotherapies: A Literature Review},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27041700}
}
EUVIMED